Marshall Wace’s Estrella Immunopharma ESLA Stock Holding History

Marshall Wace’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56,236	Closed	-$87.7K	–	3335
2025 Q4	$87.7K	Buy	+56,236	New	+$106K	﹤0.01%	2725

Other funds holding ESLA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Marshall Wace's ESLA Position: Q1 2026 in Review

Marshall Wace sold out of Estrella Immunopharma (ESLA) in Q1 2026, closing a stake of 56,236 shares — an estimated $87.7K sold.

Marshall Wace first reported a position in ESLA in Q4 2025 and held it in 1 quarter. The position peaked at $87.7K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

Marshall Wace reported no remaining Estrella Immunopharma position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 56,236 Estrella Immunopharma shares in Q1 2026, an estimated $87.7K.
Marshall Wace first reported a position in Estrella Immunopharma in Q4 2025 and held it in 1 quarter.
Marshall Wace's Estrella Immunopharma position peaked at $87.7K in Q4 2025.
16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.